Tivozanib + Enzalutamide in Adv Prostate Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by Massachusetts General Hospital
Sponsor:
Collaborator:
National Cancer Comprehensive Network
Information provided by (Responsible Party):
Dror Michaelson, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01885949
First received: June 19, 2013
Last updated: January 8, 2014
Last verified: January 2014

June 19, 2013
January 8, 2014
June 2013
December 2015   (final data collection date for primary outcome measure)
Progression Free Survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
The primary objective of this study will be to demonstrate an improvement in progression free survival in men with metastatic castration resistant prostate cancer (mCRPC) treated with tivozanib and enzalutamide.
Same as current
Complete list of historical versions of study NCT01885949 on ClinicalTrials.gov Archive Site
  • Safety and Tolerability [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
    Safety and tolerability of tivozanib and enzalutamide will be assessed. The number of patients having grades 1-4 adverse events by NCI CTC version 4.0 will be recorded.
  • Overall Survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To estimate overall survival in patients treated with tivozanib and enzalutamide
  • PSA Response rate [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To evaluate PSA response rate
  • Time to PSA Progression [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    The time to PSA progression (in months) will be evaluated in patients treated with enzalutamide and tivozanib
Same as current
Not Provided
Not Provided
 
Tivozanib + Enzalutamide in Adv Prostate Cancer
Phase 2 Combination Trial of Tivozanib and Enzalutamide in Men With Advanced Prostate Cancer

This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational combination of drugs to learn whether they work in treating a specific cancer. "Investigational" means that the combination of drugs is still being studied and that research doctors are trying to find out more about it, such as the safest dose to use and the side effects they may cause. It also means that the FDA has not yet approved the combination.

The two drugs being tested in this study are tivozanib and enzalutamide. Enzalutamide has been approved by the FDA for treatment of prostate cancer. On the other hand, tivozanib is still investigational, and has not been tested in a combination with enzalutamide before.

Enzalutamide is an androgen receptor antagonist (it blocks the activity of the male sex hormones). Prostate cancers are initially dependent on the male hormone testosterone for growth. Hormonal therapies that lower testosterone or block the ability of testosterone to act at the level of the prostate cancer are currently among the most effective treatments for prostate cancers taht have spread to other body organs (metastasized). The effectiveness of hormonal treatments, however, is not permanent, and over time many prostate cancers progress in spite of these treatments. Enzalutamide is a drug that has been proven to help delay the progression of advanced prostate cancer on average for about 8 months.

Tivozanib is an anti-angiogenesis medicine that fights different types of cancer by blocking the blood supply to the tumor, so that the tumor does not receive the nutrients it needs to grow. The main goal of this study is to determine whether the combination of tivozanib and enzalutamide is more effective in delaying the progression of disease than when enzalutamide is given alone. This study will also determine whether treatment with the combination of the tivozanib and enzalutamide will have more side effects then treatment with enzalutamide alone.

Patients will be treated in treatment cycles of 28 days (4 weeks), during which time they will take tivozanib once a day for 21 days (3 weeks) followed by a one week break from treatment. The other medication, enzalutamide, will be taken every day throughout each cycle.

Patients will be given a Study Drug Administration Diary to keep a brief record of medication administration, and to record any side effects or symptoms.

Patients will be seen in the clinic at the beginning of each cycle (every 4 weeks). During each visit they will have the following procedures: medical history, vital sign measurements, complete physical examination, performance status, routine blood tests, urine sample, prostate specific antigen (PSA) test, assessment of tumor, review of study drug administration diary, and review of current medications.

About four weeks after stopping the study drug patients will be asked to return to the research clinic for a final study visit. The following procedures will be done: medical history, vital sign measurements, brief physical examination, electrocardiogram, review of other medications used since the last visit, routine blood tests, urine sample and a review of any changes in health.

Interventional
Phase 2
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Prostate Cancer
  • Drug: Tivozanib
    Oral
    Other Name: AV-951
  • Drug: Enzalutamide
    oral
    Other Name: MDV-3100
Experimental: Experimental Treatment Arm
Tivozanib, taken daily for 21 days followed by a 7 day break Enzalutamide taken daily for 28 days
Interventions:
  • Drug: Tivozanib
  • Drug: Enzalutamide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
42
Not Provided
December 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adenocarcinoma of the prostate that is metastatic or unresectable and for which standard curative options do not exist
  • Radiographic evidence of metastatic prostate cancer
  • Progressive disease despite ongoing androgen deprivation therapy (ADT), defined as castration resistant prostate cancer (CRPC)
  • Other than ongoing prior treatment with other hormonal agents such as antiandrogens or ketoconazole must have been stopped at least two weeks prior to enrollment
  • Have received prior docetaxel-based chemotherapy for prostate cancer within the past 12 months. Such chemotherapy must have been stopped at least 3 weeks prior to the first dosing in this study
  • Life expectancy of at least 12 weeks
  • Must agree to use adequate contraception prior to study entry and for the duration of study participation

Exclusion Criteria:

  • Prior treatment with enzalutamide, TOK-001, or ARN-509
  • Participants who have received more than two prior chemotherapy regimens for metastatic CRPC
  • Receiving any other investigational anticancer agents
  • Known brain metastases
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to tivozanib or enzalutamide
  • Radiotherapy or minor surgical procedure within 2 weeks, or major surgical procedure within 4 weeks prior to administration of first dose of study drug; inadequate recovery from prior surgical procedure
  • History of seizure of condition that may predispose to seizure
  • Significant cardiovascular disease
  • Non-healing wound, bone fracture or skin ulcer
  • Active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis or other gastrointestinal condition with increased risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks prior to administration of first dose of study drug
  • Serious/active infection or infection requiring parenteral antibiotics
  • Significant thromboembolic or vascular disorders within 6 months prior to administration of first dose of study drug
  • Currently active second primary malignancy, including hematologic malignancies, except for non-melanoma skin cancers, in situ cervical cancer, and ductal or lobular carcinoma in situ of the breast
  • History of genetic or acquired immune suppression disease such as HIV; subjects on immune suppressive therapy for organ transplant
  • Inability to swallow capsules, malabsorption syndrome or gastrointestinal disease that severly affects the absorption of study drugs, major resection of the stomach or small bowel, or gastric bypass procedure
  • Significant bleeding disorders within 6 months prior to administration of first dose of study drug
  • Psychiatric disorder or altered mental status precluding informed consent or protocol-related testing
Male
18 Years and older
No
Contact: M. Dror Michaelson, MD, PhD 6177261594 dmichaelson1@partners.org
United States
 
NCT01885949
13-073
Yes
Dror Michaelson, MD, Massachusetts General Hospital
Massachusetts General Hospital
National Cancer Comprehensive Network
Principal Investigator: M. Dror Michaelson, MD, PhD Massachusetts General Hospital
Massachusetts General Hospital
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP